viewPolarean Imaging PLC

Polarean Imaging appoints former CFO of cancer therapeutics firm as new finance boss

Charles (Chuck) Osborne, Jr joins the company from oncology group Innocrin Pharmaceuticals and would start the role with immediately

Osborne will replace outgoing CFO Bill Patrick, who will take up the post of financial controller at Polarean Inc, the group’s subsidiary

Polarean Imaging Plc (LON:POLX) has appointed the former chief financial officer (CFO) of an oncology therapeutics firm as its new finance boss.

The medical imaging firm said Charles (Chuck) Osborne, Jr, who joins the company from Innocrin Pharmaceuticals Inc, would begin the role with immediate effect and will replace outgoing CFO Bill Patrick, who would take up the post of financial controller at Polarean Inc, the group’s subsidiary.

READ: Polarean Imaging signs deal with University of British Colombia

Prior to his role at Innocrin, Osborne was CFO of anti-infective therapy group Scynexis Inc (NASDAQ:SCYX).

Richard Hullihen, Polarean’s chief executive, said Osborne’s “previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function”.

Quick facts: Polarean Imaging PLC

Price: 26 GBX

Market: AIM
Market Cap: £42.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...



Polarean Imaging welcomes new strategic investor as it raises £8.4mln in new...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott after conditionally raising £8.4mln (US$10.7mln) before expenses. He says the extra cash will help to strengthen its balance sheet while it prepares for the new drug application (NDA) for its...

on 18/3/20

2 min read